10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
PFIZER INC | |||
Ticker: PFE Fiscal Year: 2020 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 25, 2021) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Revenues | $ 41,908 | 41,172 | 40,825 |
| Costs and expenses: | |||
| Cost of sales | 8,692 | 8,251 | 8,987 |
| Selling, informational and administrative expenses | 11,615 | 12,750 | 12,612 [1] |
| Research and development expenses | 9,405 | 8,394 | 7,760 |
| Amortization of intangible assets | 3,436 | 4,462 | 4,736 |
| Restructuring charges and certain acquisition-related costs | 600 | 601 | 1,058 |
| (Gain) on completion of Consumer Healthcare JV transaction | (6) | (8,086) | 0 |
| Other (income)/deductionsnet | 669 | 3,314 | 2,077 |
| Income from continuing operations before provision/(benefit) for taxes on income | 7,497 | 11,485 | 3,594 |
| Provision/(benefit) for taxes on income | 477 | 618 | (266) |
| Income from continuing operations | 7,021 | 10,867 | 3,861 |
| Income from discontinued operationsnet of tax | 2,631 | 5,435 | 7,328 |
| Net income before allocation to noncontrolling interests | 9,652 | 16,302 | 11,188 |
| Less: Net income attributable to noncontrolling interests | 36 | 29 | 36 |
| Net income attributable to Pfizer Inc. common shareholders | 9,616 | 16,273 | 11,153 |
| Earnings per common sharebasic: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.26 | 1.95 | 0.65 |
| Income from discontinued operationsnet of tax (in dollars per share) | 0.47 | 0.98 | 1.25 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.73 | 2.92 | 1.90 |
| Earnings per common sharediluted: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.24 | 1.91 | 0.64 |
| Income from discontinued operationsnet of tax (in dollars per share) | 0.47 | 0.96 | 1.23 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.71 | 2.87 | 1.87 |
| Weighted-average sharesbasic | 5,555 | 5,569 | 5,872 |
| Weighted-average sharesdiluted | 5,632 | 5,675 | 5,977 |
| [1] Exclusive of amortization of intangible assets, except as disclosed in Note 1L. | |||
| External Links | |
| PFIZER INC (PFE) Fiscal Year 2020 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |